Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Human Vaccines & Immunotherapeutics|August 23, 2013
Modern Vaccines/Adjuvants Formulation--Session 2 (Plenary II): May 15-17, 2013--Lausanne, SwitzerlandNicolas Collin
Vaccine|July 1, 2009
Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenzaNicolas Collin, Xavier de Radiguès,
Vaccine|June 21, 2011
The Vaccine Formulation Laboratory: a platform for access to adjuvantsNicolas Collin, Patrice M Dubois
Methods in Molecular Biology (Clifton, N.J.)|October 9, 2016
QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into LiposomesLivia Brunner, Christophe Barnier-Quer, Nicolas Collin
Vaccines|September 15, 2016
Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune ResponsesJohanna Poecheim, Christophe Barnier-Quer, Nicolas Collin, et al.
Pharmacological Research|February 16, 2023
Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccinesAllegra Peletta, Céline Lemoine, Thomas Courant, et al.
International Journal for Equity in Health|May 29, 2019
Equitable realization of the right to health in Haiti: how household data inform health seeking behavior and financial risk protectionMarion Cros, Eleonora Cavagnero, Jean Patrick Alfred, et al.
Nanomaterials (Basel, Switzerland)|March 29, 2017
Nanocarriers for DNA Vaccines: Co-Delivery of TLR-9 and NLR-2 Ligands Leads to Synergistic Enhancement of Proinflammatory Cytokine ReleaseJohanna Poecheim, Simon Heuking, Livia Brunner, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 16, 2016
Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticlesEleni Maria Varypataki, Ana Luisa Silva, Christophe Barnier-Quer, et al.
Vaccines|September 5, 2020
A Comparison of Intramuscular and Subcutaneous Administration of LigA Subunit Vaccine Adjuvanted with Neutral Liposomal Formulation Containing Monophosphoryl Lipid A and QS21Teerasit Techawiwattanaboon, Christophe Barnier-Quer, Tanapat Palaga, et al.
Pageof 6